Projected Income Statement: BIONOMICSSADR

Forecast Balance Sheet: BIONOMICSSADR

Fiscal Period: June 2022 2023 2024 2025 2026 2027 2028
Net Debt - - - - - - -
Change - - - - - - -
Announcement Date 8/25/22 9/29/23 11/8/24 9/29/25 9/18/26 - -
Estimates

Cash Flow Forecast: BIONOMICSSADR

Fiscal Period: June 2021 2022 2023 2024 2025 2026
CAPEX 1 0.001468 0.001544 - - - -
Change - 5.18% - - - -
Free Cash Flow (FCF) 1 -2.86 -11.89 -7.178 -7.925 0.4617 -8.339
Change - -315.64% 39.62% -10.42% 105.83% -1,906.09%
Announcement Date 8/25/21 8/25/22 9/29/23 9/30/24 9/29/25 9/18/26
1USD in Million
Estimates

Forecast Financial Ratios: BIONOMICSSADR

Fiscal Period: June 2021 2022 2023 2024 2025 2026 2027 2028

Profitability

        
EBITDA Margin (%) - -378.84% -5,147.68% -744.93% -7.21% -1,344.62% - -
EBIT Margin (%) - -399.05% -5,340.62% -773.59% -7.21% -1,401.08% - -
EBT Margin (%) - -399.85% -5,345.5% -673.59% -5.35% -1,157.51% - -
Net margin (%) - -396.36% -5,311.01% -669.82% -2.36% -1,145.66% - -
FCF margin (%) - - -3,559.36% - - - - -
FCF / Net Income (%) - - 67.02% - - - - -

Profitability

        
ROA -14.48% -18.4% -32.11% -39.58% -1.84% -19.65% - -
ROE -28.86% -41.64% -70.72% -78.44% -2.03% -61.7% - -

Financial Health

        
Leverage (Debt/EBITDA) - - - - - - - -
Debt / Free cash flow - - - - - - - -

Capital Intensity

        
CAPEX / Current Assets (%) - - - - - - - -
CAPEX / EBITDA (%) - - - - - - - -
CAPEX / FCF (%) - - - - - - - -

Items per share

        
Cash flow per share 1 - - - - - - - -
Change - - - - - - - -
Dividend per Share 1 - - - - - - - -
Change - - - - - - - -
Book Value Per Share 1 - - - - - - - -
Change - - - - - - - -
EPS 1 - - - - -0.23 -3.06 -2.43 -2.46
Change - - - - - -1,230.43% 20.59% -1.23%
Nbr of stocks (in thousands) - - - - 1,880 5,405 5,411 5,411
Announcement Date - - - - 9/29/25 9/18/26 - -
1USD
Estimates
2027 *2028 *
P/E -1.43x -1.41x
PBR - -
EV / Sales - -
Yield - -

EPS & Dividend



Y-o-Y evolution of P/E

 
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3.470
Average target price
-

Quarterly revenue - Rate of surprise